218 related articles for article (PubMed ID: 30316174)
1. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
[TBL] [Abstract][Full Text] [Related]
2. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
[TBL] [Abstract][Full Text] [Related]
3. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
[TBL] [Abstract][Full Text] [Related]
4. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis--Report of Two Cases.
Rau D; Lang M; Harth A; Naumann M; Weber F; Tumani H; Bayas A
Int J Mol Sci; 2015 Jun; 16(7):14669-76. PubMed ID: 26132570
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab.
Aguirre C; Meca-Lallana V; Sánchez P; Vivancos J
Mult Scler Relat Disord; 2019 Oct; 35():270-271. PubMed ID: 31442904
[TBL] [Abstract][Full Text] [Related]
6. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus Immunity After Alemtuzumab Induction in Desensitized Kidney Transplant Patients.
Ge S; Karasyov A; Sinha A; Petrosyan A; Lovato D; Thomas DL; Vo A; Jordan SC; Toyoda M
Transplantation; 2017 Jul; 101(7):1720-1726. PubMed ID: 27841845
[TBL] [Abstract][Full Text] [Related]
8. Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.
Adamec I; Mayer M; Ćorić M; Ruška B; Habek M
Mult Scler Relat Disord; 2020 Nov; 46():102589. PubMed ID: 33296985
[TBL] [Abstract][Full Text] [Related]
9. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.
Lambert C; Dubois B; Dive D; Lysandropoulos A; Selleslag D; Vanopdenbosch L; Van Pesch V; Vanwijmeersch B; Janssens A
Acta Neurol Belg; 2018 Mar; 118(1):7-11. PubMed ID: 29380254
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab (LEMTRADA) and multiple sclerosis. Biased evaluation, evidence of serious risks.
Prescrire Int; 2015 Mar; 24(158):69. PubMed ID: 25897458
[TBL] [Abstract][Full Text] [Related]
11. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
[TBL] [Abstract][Full Text] [Related]
12. Alemtuzumab treatment of multiple sclerosis.
Coles AJ
Semin Neurol; 2013 Feb; 33(1):66-73. PubMed ID: 23709214
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.
Ruck T; Bittner S; Wiendl H; Meuth SG
Int J Mol Sci; 2015 Jul; 16(7):16414-39. PubMed ID: 26204829
[TBL] [Abstract][Full Text] [Related]
14. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
[TBL] [Abstract][Full Text] [Related]
16. [Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].
Mori M
Brain Nerve; 2014 Oct; 66(10):1179-89. PubMed ID: 25296872
[TBL] [Abstract][Full Text] [Related]
17. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis.
Zappulo E; Buonomo AR; Moccia M; Pinchera B; Villari R; Petracca M; Lanzillo R; Scotto R; Carotenuto A; Viceconte G; Schiano Moriello N; Bruno L; Gentile I; Brescia Morra V
Mult Scler Relat Disord; 2022 Jul; 63():103814. PubMed ID: 35487032
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient.
Ishii Y; Itabashi M; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S
Intern Med; 2016; 55(6):673-5. PubMed ID: 26984089
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab for Multiple Sclerosis.
Willis MD; Robertson NP
Curr Neurol Neurosci Rep; 2016 Sep; 16(9):84. PubMed ID: 27485945
[TBL] [Abstract][Full Text] [Related]
20. Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations.
Dörr J; Baum K
Drug Des Devel Ther; 2016; 10():3379-3386. PubMed ID: 27799738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
